This is the first time in 20 years that CalPERS has changed its sole health plan provider.
The California Public Employees’ Retirement System (CalPERS) named Blue Shield of California as its sole health plan provider starting in 2025.
In a press release, Blue Shield stated that it would offer coverage to approximately 400,000 CalPERS PPO plan members in the state. CalPERS has not named a new administrator of its plan in the last 20 years.
In a press release, Blue Shield of California CEO and president Paul Markovich said, “We are thrilled to be selected and have this opportunity to expand our partnership with CalPERS. We believe our work together can serve as a model for affordable health care for the rest of the country and we're eager to get started on delivering access to cost-effective, high-quality care and service to CalPERS and its beneficiaries."
CalPERS’ chief health director also stated, “We are excited to work with Blue Shield of California, which has demonstrated a true commitment to not only make sure CalPERS members are well served, but to help change health care quality and cost for all Californians.”
Tim Lieb, senior vice president of growth at Blue Shield also said, “As the only statewide nonprofit health plan in California, we share CalPERS' commitment to improving the lives of the people we serve. We are excited to continue partnering with CalPERS and Included Health as we lead the way to a healthcare system that is worthy of our family and friends and sustainably affordable."
Blue Shield of California has also recently made new additions to its leadership team. In May of this year, the agency announced that Kassie Maroney had been named as executive vice president and chief actuary.2
In a press release issued at the time, executive vice president and chief financial officer Mike Stuart said, “Kassie Maroney brings deep experience to this position. Her strong business acumen, along with well-aligned leadership abilities in finance and underwriting are integral to this role. Her expertise will help us deliver high-quality affordable health care to the members we serve, and her background closely aligns with our north star of creating a healthcare system worthy of our family and friends that is sustainably affordable."
Earlier in May, the company also announced that Lois Quam had joined as president of Blue Shield of California, while Susan Mullaney had joined as executive vice president of strategic initiatives.3
In a press release issued at the time, Markovich said, “Lois and Susan are dynamic leaders who share our mission-driven passion to think big and be fearless in solving the kinds of complex problems we face in health care. Our current healthcare system is unsustainable and unacceptable. That's why we are running hard and fast with talented leaders to make bold moves that fundamentally change the way our healthcare system works and make it worthy of our family and friends and sustainably affordable for everyone."
In the same press release, Quam said, “I believe California can lead the nation in creative, enduring solutions in health care, and Blue Shield of California is uniquely positioned to lead that charge. I'm honored to join this talented team in making that vision a reality."
Mullaney added, “Health care needs courageous leaders—now more than ever—because we have to do things differently to transform how it works today. Clearly, Blue Shield of California has been doing that and I'm really excited to be part of this team."
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.